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Abstract
This update on chronic urticaria (CU) focuses on the preva-
lence and pathogenesis of chronic spontaneous urticaria 
(CSU), the expanding spectrum of patient-reported out-
come measures (PROMs) for assessing CU disease activity, 
impact, and control, as well as future treatment options for 
CU. This update is needed, as several recently reported find-
ings have led to significant advances in these areas. Some of 
these key discoveries were first presented at past meetings 
of the Collegium Internationale Allergologicum (CIA). New 
evidence shows that the prevalence of CSU is geographical-
ly heterogeneous, high in all age groups, and increasing. 
Several recent reports have helped to better characterize 
two endotypes of CSU: type I autoimmune (or autoallergic) 
CSU, driven by IgE to autoallergens, and type IIb autoim-
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mune CSU, which is due to mast cell (MC)-targeted autoan-
tibodies. The aim of treatment in CU is complete disease con-
trol with absence of signs and symptoms as well as normal-
ization of quality of life (QoL). This is best monitored by the 
use of an expanding set of PROMs, to which the Angioedema 
Control Test, the Cholinergic Urticaria Quality of Life Ques-
tionnaire, and the Cholinergic Urticaria Activity Score have 
recently been added. Current treatment approaches for CU 
under development include drugs that inhibit the effects of 
signals that drive MC activation and accumulation, drugs 
that inhibit intracellular pathways of MC activation and de-
granulation, and drugs that silence MCs by binding to in-
hibitory receptors. The understanding, knowledge, and 
management of CU are rapidly increasing. The aim of this 
review is to provide physicians who treat CU patients with an 
update on where we stand and where we will go. Many ques-
tions and unmet needs remain to be addressed, such as the 
development of routine diagnostic tests for type I and type 
IIb autoimmune CSU, the global dissemination and consis-
tent use of PROMs to assess disease activity, impact, and con-
trol, and the development of more effective and well-toler-
ated long-term treatments for all forms of CU.
© 2020 The Author(s)
Published by S. Karger AG, Basel
The Prevalence of Chronic Urticaria Is High in 
all Age Groups, Increasing, and Geographically 
Heterogeneous
A recently published systematic review [1] with meta-
analyses on the prevalence of chronic urticaria (CU) re-
vealed three major insights: (1) CU is just as common in 
children as it is in adults; (2) the prevalence of CU is in-
creasing; (3) there are substantial differences in the prev-
alence of CU across geographical regions.
Based on the limited published data available, the 
overall point prevalence of CU across all age groups is es-
timated at 0.7% [2, 3]. This confirms that CU is a common 
disease. Interestingly, new data also show that the preva-
lence of CU in children is as high as or higher than in 
adults, estimated on average at 1% [1]. In three studies 
that included both children and adults, the prevalence did 
not differ significantly between both age groups [4–6]. In 
a more recent study, the prevalence in children in Europe 
was 1.1% [7]. In a study from Korea, the prevalence in 
children was even higher [8]. The point prevalence of CU 
in women is higher than in men (1.3 vs. 0.8%). Looking 
at sex differences in children, a subgroup analysis yielded 
a point prevalence of 1.0% for girls and 1.1% for boys.
When all available studies that assessed point preva-
lence at different time points in the same region were 
compared, they all showed increasing point prevalence 
over time [3]. This was especially so in the studies from 
Asia (Taiwan and Korea) [5, 9]. Geographical regions 
with a high point prevalence were Latin America and Asia 
with estimates of 1.5 and 1.4%, respectively [1]. In con-
trast, North America showed by far the lowest point prev-
alence. The reasons for this are currently unclear. Global 
studies are needed.
Additional unmet needs in our understanding of the 
prevalence of CU and its increase include the frequencies 
of chronic inducible urticarias (CIndUs) as well as the 
reasons for the differences in prevalence seen in women 
versus men, but not girls versus boys, and those of pa-
tients from different parts of the world. Future epidemio-
logical studies should also clarify the rate of CU patients 
with wheals, angioedema, and both in children and adults 
as well as the duration of the different subforms of CU. 
As of now, virtually all studies on the duration of CU have 
assessed this in patients who still had the disease rather 
than in patients who had undergone spontaneous remis-
sion.
Type I and Type IIb Autoimmunity: Emerging 
Endotypes of Chronic Spontaneous Urticaria
Chronic spontaneous urticaria (CSU), the most com-
mon form of CU, presents with transient wheals (hives), 
angioedema, or both, without any definite triggers and 
reoccurrence of signs and symptoms for > 6 weeks. CSU 
is a mast cell (MC)-driven disease. The degranulation of 
skin MCs is held to be the initial event in the development 
of skin changes, such as sensory nerve stimulation, vaso-
dilation and extravasation, as well as the recruitment of 
basophils, eosinophils, and T cells, which collectively lead 
to whealing, itch, and angioedema. Over the past year, 
two groups of MC-degranulating signals have been iden-
tified and characterized: IgE autoantibodies to autoaller-
gens and autoantibodies that target activating MC recep-
tors (Fig. 1). These two types of autoimmune hypersensi-
tivity, i.e., type I autoimmunity (also called autoallergy) 
and type IIb autoimmunity, have been postulated to be 
the relevant cause in most patients with CSU [10].
In type I autoimmune CSU, autoantigens crosslink IgE 
autoantibodies on MCs and basophils to cause the release 
of vasoactive mediators (Fig. 1). A role of type I autoim-
munity in urticaria was postulated as early as 20 years ago, 
following the demonstration of IgE autoantibodies 
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against the thyroid microsomal antigen in the serum of a 
CSU patient [11]. Since then, many studies have further 
characterized the prevalence and pathogenic relevance of 
type I autoimmunity in CSU [12]: Thyroperoxidase 
(TPO) has been demonstrated to be a common and rel-
evant autoallergen in CSU. In one study, more than half 
of the 478 analyzed CSU patients were found to have el-
evated levels of IgE autoantibodies against TPO (IgE-an-
ti-TPO). In Xolair in Chronic Urticaria Induced by serum 
IgE Targeting Endoallergens, the first multicentric ran-
domized controlled CSU trial with the therapeutic anti-
IgE omalizumab, patients with IgE-anti-TPO showed a 
rate of complete response (i.e., no more wheals) of 70%, 
higher than that of any subsequent trial in which patients 
were not required to have IgE-anti-TPO. Basophils load-
ed with the IgE of CSU patients before exposure to TPO 
ex vivo show activation and mediator release [13, 14]. Re-
cently, Sánchez et al. [13] reported that 6 and 9 of 50 CSU 
patients showed a positive response to skin prick testing 
and intradermal injection of TPO, respectively. Also, 
whealing in response to TPO skin prick testing was adop-
tively transferred from CSU patients to healthy subjects 
[13].
CSU patients also have IgE autoantibodies directed to 
a large assortment of autoantigens beyond TPO, of which 
many are expressed in the skin. These include thyroglob-
ulin, tissue factor, and IL-24 [15, 16]. In one study, IgE-
anti-IL-24 was recognized by the IgE of 70% of CSU pa-
tients. Similar to TPO, exposure of basophils loaded with 
the IgE of CSU patients to subsequent incubation with 
IL-24 leads to the degranulation of MCs [16]. The IgE-
anti-IL-24 levels of patients with CSU correlate with their 
disease activity and are reduced by autologous serum 
therapy in patients who respond to this treatment [17]. 
CSU patients were also found to have elevated levels of 
IgE autoantibodies against DNA, but not of IgG against 
DNA, and in some patients, incubation of their basophils 
with DNA resulted in degranulation and mediator release 
[18].
Furthermore, it has been shown in some but not all 
studies that IgE autoantibodies are responsible for the in-
creased total IgE levels in CSU patients. In the studies 
demonstrating increased IgE autoantibodies in CSU pa-
tients, most of the IgE was found to be directed against 
autoantibodies in contrast to individuals who did not 
have CSU.
A type IIb hypersensitivity mechanism in which auto-
antibodies, usually IgG or IgM, bind to antigen on a target 
cell (Fig. 1) was first described in CSU in 1988 [19], dem-
onstrating IgG autoantibodies against IgE. Two years lat-
er, Grattan et al. [20] confirmed the presence of these au-
toantibodies in CSU patients with a positive reaction in 
the autologous serum skin test (ASST), i.e., a wheal and 
flare response to intradermal injection of their own se-
rum. Another 2 years later, IgG autoantibodies to FcεRI, 
the high-affinity receptor for IgE on MCs and basophils, 
were described in CSU patients [21]. Very recently, CSU 
patients were found to also have IgM and IgA autoanti-
bodies to FcεRI [22]. More CSU patients had IgM auto-
antibodies to FcεRI (60%) than IgG against FcεRI (24%), 
and elevated levels of IgM against FcεRI, but not of IgG 
against FcεRI, were linked to low blood basophil and eo-
sinophil counts, markers of high CSU disease activity 
[22]. The concept that type IIb autoimmune mechanisms 
can drive CSU is further supported by the results of baso-
phil tests. The serum of a subpopulation of CSU patients 
activates heterologous basophils, and this basophil-acti-
vating serum activity is linked to the presence of autoan-
tibodies against FcεRI and positive ASST responses [23, 
24].
Several independent, albeit indirect, lines of evidence 
suggest that type I autoimmune and type IIb autoimmune 
CSU patients differ in their disease features, laboratory 
markers, and response to treatment (Table 1). Based on 
the comparison of CSU patients who do or do not express 
Allergen
Autoallergen
IgE
FcεRI
IgG anti-FcεRI
IgG anti-IgE
Autoimmunity type I
Autoimmunity type IIb
Fig. 1. Endotypes of CSU. In CSU, MCs are thought to be activat-
ed in most patients by IgE autoantibodies to autoallergens (type I 
autoimmunity or autoallergy) or IgG autoantibodies targeting ac-
tivating MC receptors (type IIb autoimmunity). CSU, chronic 
spontaneous urticaria; MC, mast cell.
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markers of type IIb autoimmunity (autoantibodies, baso-
phil tests, and/or ASST), type IIb autoimmune CSU pa-
tients have been suggested to have higher disease activity 
and longer disease duration as well as higher rates of co-
morbid autoimmunity. Basopenia and eosinopenia may 
also be more common in these patients.
In the recent PURIST study, the first to characterize 
CSU patients who are positive for all three defining mark-
ers of type IIb autoimmune CSU, i.e., IgG-anti-FcεRI/
IgE-positive, basophil test-positive, and ASST-positive, 
8% of 184 patients were triple-positive, i.e., had bona fide 
type IIb CSU [25]. These patients showed higher IgG-
anti-TPO levels and higher rates of elevated IgG-anti-
TPO as well as lower IgE levels and higher rates of low IgE 
as compared to triple-negative patients. In fact, the IgG-
anti-TPO/IgE ratio was found to be the best predictor of 
type IIb autoimmune CSU. Other markers that have been 
suggested to be different in type IIb versus type I CSU pa-
tients include C-reactive protein and antinuclear anti-
bodies (Table 1).
The efficacy of anti-IgE treatment with omalizumab or 
ligelizumab supports both type I and type IIb autoim-
mune pathomechanisms in CSU. Omalizumab reduces 
the levels of IgE, the driver of type I autoimmune CSU, 
and of its high-affinity receptor FcεRI, the target of type 
IIb autoantibodies. More importantly, type I and type IIb 
autoimmune CSU patients treated with anti-IgE differ in 
their rates of response and in their speed of onset of im-
provement [26–30]. Most CSU patients treated with 
omalizumab become symptom-free within the first 
month of their first injection. This is in line with type I 
autoimmunity, where anti-IgE rapidly binds free IgE, in-
cluding IgE against autoantigens, and IgE/anti-IgE com-
plexes bind autoallergens, thereby reducing MC degranu-
Table 1. Features of type I and type IIb autoimmune CSU
Features Type I versus type IIb autoimmunity
Autoantibodies auto-IgE (e.g., against TPO, TG, TF, IL-24, dsDNA) in type I [12, 13, 15, 111], 
auto-IgG (against IgE, FcεRI) in type IIb [112–114]
Diagnosis total auto-IgE and specific IgE to autoallergens1 in type I [115], triple positivity: 
BHRA/BAT+ASST+WB/ELISA+ in type IIb [24, 25]
Disease activity/severity tends to be higher in type IIb [12, 14, 25, 111]2
Disease duration tends to be longer in type IIb as shown in some [116, 117] but not all [25] studies
Rates of concomitant autoimmune diseases tend to be higher in type IIb [25, 118–121]
Rates of concomitant allergic diseases might be higher in type I [119]
Total IgE levels low in type IIb and normal or high in type I [14, 25]
Basopenia rates might be higher in type IIb [24, 111]2
Eosinopenia rates tend to be higher in type IIb [122]
C-reactive protein levels may be higher in type IIb [25, 123]
ANA positivity rates may be higher in type IIb [124]
Responder rates to sgAHs may be lower in type IIb [122–125]
Responder rates to omalizumab high in type I [28] and low in type IIb [62, 122, 126]
Speed of response to omalizumab slow in type IIb [127]
Immunosuppressive therapy can be effective in type IIb [128–134]3
TPO, thyroperoxidase; TG, thyroglobulin; TF, tissue factor; IL, interleukin; dsDNA, double-stranded DNA; BHRA, basophil 
histamine release assay; BAT, basophil activation test; ASST, autologous serum skin test; WB, Western blot; ELISA, enzyme-linked 
immunosorbent assay; CRP, C-reactive protein; ANA, antinuclear antibodies; sgAHs, second-generation antihistamines. 1 Measured by 
ELISA or radioimmunoassay. 2 In one study, IgE-anti-IL-24 levels showed a correlation with disease activity and a negative correlation 
with blood basophil counts. 3 Cyclosporine, plasmapheresis, rituximab, intravenous immunoglobulins, methotrexate, mycophenolate 
mofetil. Most studies are case reports.
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lation. Some CSU patients take months to respond to 
omalizumab, and this is in line with type IIb autoimmu-
nity, where the reduction of free IgE results in the slow 
loss of membrane-bound FcεRI from skin MCs, the target 
of type IIb-driving autoantibodies.
Future studies need to characterize in detail the role 
and relevance of type I and type IIb autoimmunity in 
CSU. Standardized and validated diagnostic tests for IgE 
autoantibodies to autoallergens and for relevant MC-ac-
tivating autoantibodies need to be developed to better de-
fine these CSU endotypes and their differences. A clearer 
picture of the prevalence, mechanisms, and clinical pro-
files of type I and type IIb autoimmune CSU will help to 
develop targeted therapies and facilitate optimal treat-
ment of both subpopulations of CSU patients.
Recent reports [31–35] suggest that additional endo-
types of CSU may exist, with evidence pointing to a role 
of factors of the coagulation pathway, ligands of the MAS-
related G protein-coupled receptor X2 (MRGPRX2), ba-
sophils, alarmins, and other signals in the pathogenesis of 
CSU. More research is needed to clarify whether mecha-
nisms of skin MC degranulation other than type I and 
type IIb autoimmune activation support the existence of 
distinct and separate endotypes.
Use of Patient-Reported Outcome Measures 
Improves the Management of CU
Why We Should Measure Disease Activity, Impact, 
and Control in Patients with CU
Patient-reported outcome measures (PROMs) are es-
sential for optimizing the management of CU [36, 37]. 
They are also of key importance for assessing treatment 
effects in clinical trials. Over the past years, disease-spe-
cific PROMs have been developed for CU (Table 2). They 
are widely used in clinical practice and trials, and they as-
sess disease activity, impact, or control. Why is it impor-
Table 2. PROMs in CSU and areas of use
UAS CU-Q2oL UCT AAS AE-QoL AECT
Applicable in patients with: 
Wheals and no angioedema
Wheals and angioedema
No wheals and angioedema
+
+
–
+
+
–
+
+
+
–
+
+
–
+
+
–
+
+
Number of items 2 23 4 5 17 4
Retrospective assessment 
(recall period)
– + 
2 weeks
+ 
4 weeks
– + 
4 weeks
+
4 weeks
3 months
Prospective assessment 
(frequency)
+
1× or 2×/day
– – +
1×/day
– –
MCID 11 3–153 3 8 6 not yet 
established
Cost-free for: 
Patient management 
Academic research
Industry studies
+
+
+
+
+
–
+
+
–
+
+
–
+
+
–
+
+
–
Language/country versions 
available1, 2
+ Italian, German, Greek, 
Hebrew, Korean, Persian, 
Polish, Portuguese, 
Spanish, Thai, Turkish
>20 language 
versions 
available2
>70 language 
versions 
available2
>25 language 
versions 
available2
German, 
American 
English
AAS, Angioedema Activity Score; AECT, Angioedema Control Test; AE-QoL, Angioedema Quality of Life Questionnaire; CSU, chronic spontaneous 
urticaria; CU-Q2oL, Chronic Urticaria Quality of Life Questionnaire; MCID, minimal clinically important difference; PROMs, patient-reported outcome 
measures; UAS, Urticaria Activity Score; UCT, Urticaria Control Test. 1 The UAS is available in several languages. The original source is the EAACI/GA2LEN/
EDF/WAO urticaria guideline. Due to its easy structure, the UAS is usually translated but not formally linguistically validated. 2 For more details with regard 
to available language versions of the AAS, AE-QoL, UCT, and AECT go to www.moxie-gmbh.de. Additional language/country versions may be or are in 
preparation; for more information, please contact Moxie at info@moxie-gmbh.de). 3 The MCID of the CU-Q2oL has been assessed in two independent 
studies performed in different patient collectives in Europe and Asia. While one study found an MCID of 3 points [46], the MCID identified in the other 
study was higher with 15 points [134].
Maurer et al.Int Arch Allergy Immunol6
DOI: 10.1159/000507218
tant to obtain information on these three aspects of CU? 
Disease activity (i.e., symptom burden), disease impact 
(i.e., impairment of quality of life [QoL]), and the control 
that patients have over their disease are concepts that are 
linked. High disease activity often comes with low QoL 
and low levels of disease control. However, disease activ-
ity only moderately correlates with QoL impairment in 
patients with CSU [38]. In other words, some patients 
exhibit markedly impaired QoL although their symptom 
burden is rather low. Other patients show high disease 
activity, but only moderately impaired QoL. The reasons 
for this are largely unknown, but may include the pres-
ence or absence of effective coping strategies or of comor-
bid diseases, such as depression and anxiety, which are 
common in CU patients [39–41]. What is clear though is 
that the aims of effective treatment, i.e., absence of signs 
and symptoms, normalization of QoL, and complete con-
trol, are best achieved when assessed by appropriate tools.
What Tools Should Be Used to Assess Patients with 
CSU for Disease Activity, Impact, and Control?
Patients with CSU present with wheals, angioedema, 
or both, which is important in the correct selection of the 
PROMs to use. In patients with wheals (with or without 
angioedema), the Urticaria Activity Score (UAS) [42–45], 
the Chronic Urticaria Quality of Life Questionnaire (CU-
Q2oL) [46–49], and the Urticaria Control Test (UCT) 
[50–54] are the PROMs of choice to measure disease ac-
tivity, impact, and control, respectively. In patients with 
predominant angioedema (with or without wheals), the 
Angioedema Activity Score (AAS) [55, 56], the Angio-
edema Quality of Life Questionnaire (AE-QoL) [57–59], 
and the Angioedema Control Test (AECT) [59] should be 
used (Table 2).
The UAS7 records, over 7 consecutive days, the daily 
number of wheals and the intensity of itch. It is the guide-
line-recommended gold standard for measuring disease 
activity in CSU patients with wheals [60, 61] (Table 2). 
The two available versions of the UAS7 differ slightly in 
that they require either a twice-daily or once-daily docu-
mentation and in their categories for daily numbers of 
wheals. Both versions yield comparable results [43, 44]. 
The once-daily UAS is preferred for routine clinical use: 
Patients only need to document their wheals and itch 
once every day, it has been thoroughly validated [60], its 
minimal clinically important difference (MCID) of 11 
points is well characterized [42], and it has been used in 
numerous randomized controlled trials and real-life 
studies [17, 62–64]. The UAS7 has several limitations. It 
has not been validated in children, although a modified 
version has been reported [65]. It is not suitable for as-
sessing disease activity in patients with CIndU. The docu-
mentation of itch and its intensity may reflect non-CSU-
related itch. It does not entail angioedema, a common and 
important clinical manifestation of CSU. The prospective 
character of the UAS7 makes an ad hoc evaluation impos-
sible, as the results are only available at the next appoint-
ment after its administration.
CSU patients experience markedly impaired QoL. 
General QoL questionnaires and QoL instruments devel-
oped for patients with dermatological diseases such as the 
Dermatology Life Quality Index, the Children’s Derma-
tology Life Quality Index, the Dermatology Quality of 
Life Scales, and the Dermatology-Specific Quality of Life 
instrument have been used in CSU [66, 67]. While these 
tools are well suited to compare QoL impairment in pa-
tients with CSU with that in patients with other diseases, 
they do not provide information on CSU-specific aspects 
of QoL impairment nor on its changes over time, e.g., in 
response to treatment [68]. The CU-Q2oL was developed 
to assess the QoL impairment specific to CSU [47, 68] 
(Table 2). It is the guideline-recommended QoL tool for 
CSU [61] and available in many languages [48, 49, 69–
72]. The CU-Q2oL shows good sensitivity to change, and 
its MCID has been found to be 3–15 (3 and 15 in inde-
pendent studies and patient collectives from Europe and 
Asia). It has been used in many clinical studies, including 
pharmacological randomized controlled trials [28, 73, 
74]. The CU-Q2oL also has limitations. Most important-
ly, it was not specifically designed to assess the QoL im-
pairment due to angioedema, which occurs in many pa-
tients and can impact on their disease-specific QoL, and 
therefore it is not useful in patients with CSU predomi-
nantly affected by angioedema. Also, there is no version 
for the use in children, and it is not suitable for CIndU.
Disease control is a major treatment aim in CSU, and 
the UCT was specifically developed and validated to mea-
sure this in all forms of CU, including CIndU. The UCT 
is a 4-question retrospective PROM with a minimum val-
ue of 0 points (no control) and a maximum value of 16 
points (complete control). A score of ≤11 points indicates 
poorly-controlled urticaria, whereas a score of ≥12 points 
indicates well-controlled disease. The UCT strongly cor-
relates with the UAS [54, 75], has high levels of validity 
and reliability, and accurately identifies patients with in-
sufficiently controlled disease. Its MCID is 3 points [52, 
53]. No version for children is available as of yet.
The AAS is the tool of choice for the assessment of dis-
ease activity in patients with CSU who present with recur-
rent angioedema without wheals and in patients where 
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angioedema is a predominant factor. Like the UAS, the 
AAS is a prospective, diary-type tool. Patients document 
every day for 4 weeks (AAS28) whether angioedema oc-
curred during the last 24 h, in which case five additional 
questions on severity and impact are answered [56]. The 
AAS shows high levels of validity and test-retest reliabil-
ity and is sensitive to changes of angioedema activity over 
time, with an MCID of 8 points for the 7-day AAS (AAS7). 
The AAS has also been used in recent randomized con-
trolled trials [74, 76].
The AE-QoL is the first symptom-specific PROM to 
assess angioedema-specific QoL impairment in patients 
with CSU [58]. It consists of 17 questions with 5 answer 
options each scored from 0 to 4 points, which are summed 
up to a total score but fall in four different domain scores 
(“functioning,” “fatigue/mood,” “fears/shame,” “food”), 
which are each displayed on a 0–100 scale The AE-QoL 
demonstrates high sensitivity to change, and its MCID is 
6 points [59]. The AE-QoL is available in many different 
languages and has been used in randomized controlled 
clinical trials [74, 76]. Again, no version for children is 
available yet.
The AECT is a novel tool that quantifies disease con-
trol in CSU patients with angioedema as well as in pa-
tients with other forms of recurrent angioedema [77, 78]. 
The AECT is a retrospective PROM. Two versions exist, 
one with a 4-week recall period and one with a 3-month 
recall period. The AECT consists, like the UCT, of only 
four questions. It is easy to administer, easy to complete, 
and easy to score.
What Tools Should Be Used to Assess Disease Activity 
and Control in Patients with CIndU?
Disease activity in CIndU is assessed by testing pa-
tients for their trigger thresholds. Patients with low dis-
ease activity have high trigger thresholds and vice versa. 
In cold urticaria for example, patients with high disease 
activity can be made to develop wheals by exposure to 
warmer temperatures (e.g., 20  ° C) than those required to 
produce whealing in patients with low disease activity 
(e.g., 8   ° C). Protocols and test devices are available for 
threshold testing in cold urticaria, symptomatic dermo g-
raphism, cholinergic urticaria, pressure urticaria, and 
solar urticaria [79]. Cold urticaria patients for example 
are assessed for their individual critical temperature 
thresholds, i.e., the warmest temperature that is cold 
enough to produce a wheal, with the help of the Temptest 
[80]. Trigger threshold measurements for determining 
disease activity in patients with CIndU can be comple-
mented by the use of CIndU-specific disease activity 
scores, such as the Cholinergic Urticaria Activity Score 
[81], that should be validated. Disease activity scores for 
CIndUs take into account the actual daily exposure of pa-
tients to relevant triggers. CIndU-specific QoL question-
naires are available for some CIndUs, for example the 
Cholinergic Urticaria Quality of Life Questionnaire for 
cholinergic urticaria [82], but not all. Disease control in 
patients with CIndU is measured with the UCT.
PROMs in CU: Unmet Needs and Questions to  
Be Addressed
As of now, none of the urticaria-specific PROMs de-
veloped are available for use in children. The UAS7, CU-
Q2oL, and UCT as well as the AAS, AE-QoL, and AECT 
should be validated in adolescents, and corresponding 
tools for younger children must be developed. The same 
holds for the PROMs that were recently developed for 
CIndUs. Many PROMs, but also CIndU trigger threshold 
tests, have not yet been investigated for their MCIDs, 
which is needed for their optimal use in clinical trials and 
routine specialist practice. The global dissemination of 
available PROMs needs to be increased. Cross-cultural 
adaptations, translations, and the validation of PROMs 
are needed for international studies and for comparing 
patients from different regions of the world. For this, ap-
propriate procedures must be followed to ensure that 
questionnaires are adapted to local conditions and that 
equivalent versions are produced.
Emerging MC-Targeted Treatment Options for CU
MCs are the critical effector cells in urticaria; there-
fore, targeting MC activity is a promising treatment ap-
proach [83]. Here, the guideline recommends as third- 
and fourth-line treatments omalizumab and cyclosporine 
for CU. Omalizumab inhibits MC activation via the IgE 
receptor and cyclosporine interferes with MC signal 
transduction and activation. The next generation of 
MC-targeted treatments for CU fall into three groups: 
(1) compounds that inhibit the effects of signals that drive 
MC activation and numbers, (2) compounds that inhibit 
intracellular pathways of MC activation and degranula-
tion, and (3) compounds that silence MCs by binding to 
inhibitory receptors (Fig. 2).
Drugs Inhibiting the Effects of Signals That Drive  
MC Activation and Numbers
Activation of skin MCs via FcεRI has been shown to 
drive the development of the signs and symptoms of CSU, 
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and treatment with omalizumab, an anti-IgE antibody, is 
effective in CSU [84–91]. Omalizumab has been shown 
to dissociate pre-bound IgE from MCs and basophils, re-
sulting in a decrease in degranulation [92]. Ligelizumab 
is another humanized monoclonal anti-IgE antibody 
with a 50-fold higher affinity to IgE than omalizumab. It 
was recently tested in a phase II multicenter randomized 
controlled trial against placebo and omalizumab. In this 
trial, ligelizumab demonstrated superiority to both pla-
cebo and omalizumab and was characterized by a rapid 
onset of action and dose-dependent efficacy [63]. Inter-
estingly, ligelizumab also showed a longer time to relapse 
after the last injection, i.e., 10 versus 4 weeks with omali-
zumab. Phase III studies are ongoing in adults and ado-
lescents with CSU. This clinical efficacy of ligelizumab 
may involve effects of this molecule on IgE production by 
B cells [93].
The alarmins and innate type 2 immunity-inducing 
cytokines IL-33, IL-25, and thymic stromal lymphopoi-
etin all have effects on MCs and have been implicated in 
the pathogenesis of CSU [34, 94]. For example, the wheals 
of CSU patients show markedly more cells that express 
IL-33, IL-25, and thymic stromal lymphopoietin as com-
pared to their nonlesional skin and the skin of control 
subjects [34]. Therefore, IL-33, IL-25, and thymic stromal 
lymphopoietin should be explored as targets of novel 
treatment strategies for CSU.
Skin MCs express Kit, the receptor for stem cell fac- 
tor, which is the major driver of MC differentiation, acti-
vation, migration, proliferation, and survival [95]. MC 
numbers are increased in the skin of CSU patients, which 
may be due to the effects of stem cell factor, which is also 
a potent activator of MCs [96, 97]. Reducing the number 
of MCs may help patients with CSU. Neutralization of 
stem cell factor with anti-stem cell factor may reduce MC 
numbers and inhibit MC activation.
MCs express receptors for the Th2 cytokines IL-4 and 
IL-5. Both cytokines have been shown to promote MC 
survival and to prime them for their FcεRI-mediated pro-
duction and secretion of proinflammatory cytokines [98, 
99]. IL-4 levels are elevated in the serum of patients with 
CSU, and IL-4-expressing cells are increased in the skin 
of CSU patients [100, 101]. Recently dupilumab, which 
inhibits IL-4 and IL-13 effects through blockade of their 
shared IL-4α receptor subunit, was shown to benefit pa-
tients with refractory CSU unresponsive to omalizumab 
[102]. The effects of dupilumab in CU are currently being 
assessed in two phase II randomized clinical trials, one in 
CSU and one in cholinergic urticaria.
IL-5, in addition to its effects on MCs, may contribute 
to the pathogenesis of CSU by recruiting eosinophils and 
basophils to lesional skin sites, where they are often found 
in high numbers. Benralizumab, an anti-IL-5 receptor an-
tibody, as well as the anti-IL-5 antibodies mepolizumab 
and reslizumab have been successfully used to treat pa-
tients with CSU and CIndU [103, 104]. Benralizumab and 
mepolizumab are currently in CSU trials.
Several additional receptors, such as the complement 
C5a receptor (C5aR, CD88) and MRGPRX2, are ex-
pressed by MCs and have been proposed to be the targets 
of signals that drive the development of the signs and 
symptoms of CU. C5aR is expressed by skin MCs, but not 
lung or other MCs, and the degranulation of MCs via the 
MC-activating autoantibodies of type IIb autoimmune 
CSU patients is, at least in part, mediated by activation of 
C5aR [105, 106]. MRGPRX2, like C5aR, is preferentially 
expressed by skin MCs, where its expression is upregu-
lated in patients with severe CSU [32]. Substance P, major 
basic protein, and eosinophil peroxidase induce hista-
mine release from human skin MCs through activation of 
MRGPRX2 independent of the NK1 receptor [32]. Fur-
thermore, the levels of substance P, a neuropeptide and 
agonist of both MRGPRX2 and the NK1 receptor, are in-
FcεRI
C5aR
CRTH2KIT
ST2
Btk
Syk
MRGPRX2 IL-4R
IL-5R
TSLPR
CD300a
CD200R Siglec-8
Fig. 2. MC-targeted treatments for CU under development. Ex-
amples of activating (upper half) or inhibiting (lower half) recep-
tors and signaling molecules (within the cell) that are currently 
under development for the treatment of CU. Btk, Bruton’s tyrosine 
kinase; CU, chronic urticaria; MC, mast cell; Syk, spleen tyrosine 
kinase.
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creased in the serum of CSU patients and correlate with 
disease activity [107, 108]. Thus, targeting MRGPRX2 
and/or its agonists (e.g., substance P) is a promising 
mechanism for decreasing MC activation in patients with 
CSU.
Drugs That Inhibit Intracellular Pathways of MC 
Activation and Degranulation
Bruton’s tyrosine kinase and spleen tyrosine kinase are 
key players in the transduction of signals downstream of 
the high-affinity IgE receptor FcεRI. Inhibitors of Bru-
ton’s tyrosine kinase or spleen tyrosine kinase inhibit the 
degranulation of human MCs [109, 110]. Treatment with 
a Bruton’s tyrosine kinase inhibitor inhibits IgE- and 
MC-mediated responses in mice and humans [110]. Two 
Bruton’s tyrosine kinase inhibitors, Fenebrutinib and 
Remibrutinib, are currently under development for the 
oral treatment of patients with CSU, and the spleen tyro-
sine kinase inhibitor GSK2646264 is in clinical trials for 
cold urticaria and CSU.
Drugs That Silence MCs by Binding to Inhibitory 
Receptors
The vast majority of receptors expressed by MCs are 
activating receptors, i.e., their engagement by ligands re-
sults in degranulation, migration, differentiation, or pro-
liferation. A small set of MC receptors are inhibitory re-
ceptors that, upon engagement by ligands, silence MCs 
and inhibit their activation including degranulation. Si-
glec-8 and CD200Ra are two of these inhibitory MC re-
ceptors, and antibodies targeting them are currently un-
der development for CU. For example antolimab, a 
monoclonal antibody that targets Siglec-8, was shown to 
inhibit MC activation and to deplete eosinophils. Anto-
limab was tested in a phase IIa, open-label pilot study in 
patients with omalizumab-naïve and omalizumab-re-
fractory CSU as well as patients with symptomatic der-
mographism or cholinergic urticaria. The engagement of 
CD200Ra by agonist antibodies also inhibits MC activa-
tion and degranulation [111]. The CD200Ra-targeted an-
tibody LY3454738 is currently under development for 
CSU.
Summary, Conclusion, and Outlook
CU is a heterogeneous, persistent, severely debilitating 
and often poorly controlled disease. Recent findings sug-
gest that the prevalence of CU and its subforms may be 
more heterogeneous than previously thought and in need 
of further studies, across all age groups. Despite many 
important recent insights on the pathogenesis of CU, the 
endotypes and pathomechanisms of CSU are still insuf-
ficiently characterized and the causes of CIndU remain 
unknown. Autoallergy and type IIb autoimmunity ap-
pear to be distinct endotypes of CSU, but better tests are 
needed to identify patients with one or the other or nei-
ther. This is needed to optimize the treatment of patient 
subgroups with the drugs available today and to develop 
treatments that can prevent all of the subforms of CU, al-
ter their course, and cure patients. Antihistamines and 
omalizumab are the only currently licensed treatments, 
and additional and better treatments for CU are needed, 
especially for CIndU. The development of novel treat-
ments for CIndUs and CSU also needs instruments that 
allow to assess their efficacy. Significant progress has been 
made with this over the past years, but more efforts are 
needed to extend the existing tools to children, to develop 
and validate tools for all forms of CU, and to make urti-
caria and angioedema PROMs available and their use 
routine practice on a global scale. The future of urticaria 
drug development has never been more promising, with 
several strategies being pursued.
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